Esmolol Hydrochloride

Phase 3Small molecule

NNovalead Pharma Private Limited

Esmolol Hydrochloride is one of 45 small molecule programs targeting Septic Shock. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

EsmololRecruiting

Septic ShockPreclinical

Active, not recruiting

EsmololPhase 3

Recruiting

Competition

Competitive Landscape

72 competitors in Septic Shock

#DrugCompanyPhaseTrials

Proamatine

Takeda

Approved

4 2

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

14 3

Pitressin

AAultman Health Foundation

Approved

11 4

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

5 5

Zocor

OOrganon and Co

Approved

1 6

Florinef

Jazz Pharmaceuticals

Phase 3

5 7

Carnitor

LLeadiant Biosciences, Inc.

Cyklokapron

Methylthioninium Chloride

PProvepharm SAS

Phase 3

10 10

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Pain, Acute

NCT07846722

Clinical

Trials by Indication[1]

Esmolol3 trials

A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers

Completed·AAOP Orphan Pharmaceuticals AG·Phase 1·NCT01652898·12 enrolled

Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.

Recruiting·CCiusss de L'Est de l'Île de Montréal·Phase 4·NCT06291363·64 enrolled

A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

Completed·AAOP Orphan Pharmaceuticals AG·Phase 2·NCT01313143·16 enrolled

Diabetic Foot2 trials

Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers

Completed·NNovalead Pharma Private Limited·Phase 3·NCT03998436·176 enrolled

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

Completed·NNovalead Pharma Private Limited·Phase 1/2·NCT01113515·44 enrolled

Septic Shock1 trial

Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock

Completed·XXinchen Wang·N/A·NCT06169475·14 enrolled

Post Operative Cognitive Dysfunction1 trial

Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction

Unknown status·—·Phase 1/2·NCT03892512·58 enrolled

Postoperative Recovery1 trial

The Impact of Esmolol Administration on Postoperative Recovery

Unknown status·—·N/A·NCT05567822·70 enrolled

2 more indications

Hypotension1 trial

Effect of Controlled Hypotension on Cerebral Oxygen Saturation

Completed·IIstanbul University·Phase 4·NCT02967029·150 enrolled

Pain, Acute1 trial

The Impact of Intraoperative Esmolol and Dexmedetomidine Administration on Opioid Consumption in Laparoscopic Gynecological Procedures: A Double-blinded Randomized Study

Recruiting·VVasiliki Samartzi·Preclinical·NCT07846722·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Esmolol Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Esmolol Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Esmolol Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novalead Pharma Private Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNovalead Pharma Private Limited

Esmolol Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Esmolol3 trials

Diabetic Foot2 trials

Septic Shock1 trial

Post Operative Cognitive Dysfunction1 trial

Postoperative Recovery1 trial

Hypotension1 trial

Pain, Acute1 trial

References

Drug Info

Quick Facts

Related News